SCHEMBL535645

SCHEMBL535645

CCOc1ccccc1[C]=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 4/20 0.48
MAPT P10636 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GLA P06280 1/20 0.48
HCRTR1 O43613 2/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PTPRC P08575 1/20 0.40
CYP2C9 P11712 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.39
DAO P14920 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL910513 0.84 CYP1A2 (0.43) ALDH1A1L3MBTL1MAPTNPSR1GAA
SCHEMBL9787731 0.84 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL11721276 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL195415 0.82 CYP1A2 (0.55) L3MBTL1MAPTNPSR1GAACYP1A2
SCHEMBL2244225 0.81 CYP3A4 (0.51) ALDH1A1L3MBTL1MAPTNPSR1CYP1A2
SCHEMBL947129 0.81 PTGDR2 (0.38) ALDH1A1NPSR1GAAKDM4E
SCHEMBL2121240 0.80 LMNA (0.54) ALDH1A1MAPTNPSR1CYP1A2CYP2C19
SCHEMBL6223243 0.80 LMNA (0.54) ALDH1A1MAPTNPSR1CYP1A2CYP2C19
SCHEMBL7830925 0.80 LMNA (0.54) ALDH1A1MAPTNPSR1CYP1A2CYP2C19
SCHEMBL8453578 0.80 LMNA (0.54) ALDH1A1MAPTNPSR1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11596716-B2 Compounds and matrices for use in bone growth and repair HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2023-03-07 US claimed
CN-114933620-A Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-08-23 CN claimed
CN-108290919-B Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-06-17 CN claimed
US-20220106349-A1 Compounds EPIENDO PHARMACEUTICALS EHF (IS) 2022-04-07 US claimed
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties EPIENDO PHARMACEUTICALS EHF (IS) 2022-02-01 US claimed
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2021-05-13 US claimed
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties EPIENDO PHARMACEUTICALS EHF (IS) 2020-10-08 US claimed
EP-3708573-A1 AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES EpiEndo Pharmaceuticals ehf. (IS) 2020-09-16 EP claimed
US-10723752-B2 Azithromycin derivatives with epithelial barrier enhancement properties EPIENDO PHARMACEUTICALS EHF (IS) 2020-07-28 US claimed
EP-3377511-B1 AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES EPIENDO PHARMACEUTICALS EHF (IS) 2020-05-13 EP claimed
US-6262269-B1 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries TREGA BIOSCIENCES, INC. 2001-07-17 US claimed
WO-2000031063-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2000-06-02 WO claimed
EP-1001943-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM Aventis Pharma S.A. (FR) 2000-05-24 EP claimed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 EP claimed
EP-0977989-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2000-02-09 EP claimed
WO-1999003843-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1999-01-28 WO claimed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO claimed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO claimed
US-4198205-A SULFONIC ACID-FREE DISPERSE DYES BASF AKTIENGESELLSCHAFT (DE) 1980-04-15 US claimed
US-4006163-A POLYESTERS CIBA-GEIGY CORPORATION (US) 1977-02-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596716-B2 Compounds and matrices for use in bone growth and repair BMP2, BMP4, BMP6 ALDH1A1 1413/4885L3MBTL1 4015/4885MAPT 4739/4885
US-20220106349-A1 Compounds CFTR, AQP1, CTSA ALDH1A1 1837/4885L3MBTL1 2034/4885MAPT 4502/4885
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties CFTR, AQP1, CTSA ALDH1A1 2483/4885L3MBTL1 2932/4885MAPT 4718/4885
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR BMP2, BMP4, BMP6 ALDH1A1 1413/4885L3MBTL1 4015/4885MAPT 4739/4885
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties CFTR, AQP1, CTSA ALDH1A1 2483/4885L3MBTL1 2932/4885MAPT 4718/4885
US-10723752-B2 Azithromycin derivatives with epithelial barrier enhancement properties CFTR, AQP1, CTSA ALDH1A1 2483/4885L3MBTL1 2932/4885MAPT 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.